For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed at $29.99 down -1.38% from its previous closing price of $30.41. In other words, the price has decreased by -$1.38 from its previous closing price. On the day, 0.53 million shares were traded. CRNX stock price reached its highest trading level at $30.38 during the session, while it also had its lowest trading level at $29.8.
Ratios:
For a deeper understanding of Crinetics Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.53 and its Current Ratio is at 22.53. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on March 25, 2025, initiated with a Buy rating and assigned the stock a target price of $60.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 12 ’25 when Betz Stephen F. sold 97,483 shares for $32.23 per share. The transaction valued at 3,141,877 led to the insider holds 99,713 shares of the business.
STEPHEN BETZ bought 97,483 shares of CRNX for $3,151,625 on Jun 12 ’25. On Mar 19 ’25, another insider, Pizzuti Dana, who serves as the Chief Med and Dev Officer of the company, sold 2,515 shares for $34.20 each. As a result, the insider received 86,021 and left with 72,233 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 2848813056 and an Enterprise Value of 1586162048. For the stock, the TTM Price-to-Sale (P/S) ratio is 7804.07 while its Price-to-Book (P/B) ratio in mrq is 2.24. Its current Enterprise Value per Revenue stands at 2087.055 whereas that against EBITDA is -4.247.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.28, which has changed by -0.33043092 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $62.53, while it has fallen to a 52-week low of $24.10. The 50-Day Moving Average of the stock is -4.67%, while the 200-Day Moving Average is calculated to be -29.48%.
Shares Statistics:
For the past three months, CRNX has traded an average of 894.35K shares per day and 571410 over the past ten days. A total of 93.53M shares are outstanding, with a floating share count of 86.67M. Insiders hold about 7.49% of the company’s shares, while institutions hold 104.99% stake in the company. Shares short for CRNX as of 1749772800 were 10321299 with a Short Ratio of 11.54, compared to 1747267200 on 10163817. Therefore, it implies a Short% of Shares Outstanding of 10321299 and a Short% of Float of 12.540000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The company has 11.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$1.17, with high estimates of -$1.02 and low estimates of -$1.32.
Analysts are recommending an EPS of between -$4.08 and -$4.77 for the fiscal current year, implying an average EPS of -$4.41. EPS for the following year is -$4.6, with 13.0 analysts recommending between -$3.13 and -$6.17.
Revenue Estimates
A total of 14 analysts have provided revenue estimates for CRNX’s current fiscal year. The highest revenue estimate was $9.14M, while the lowest revenue estimate was $1.7M, resulting in an average revenue estimate of $4.99M. In the same quarter a year ago, actual revenue was $1.04MBased on 14 analysts’ estimates, the company’s revenue will be $44.69M in the next fiscal year. The high estimate is $108.78M and the low estimate is $26M.
